Apotex Inc.

Privately held: no public share price

Assets

(5 total)
5Total Assets
5Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule
Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathy
Approved
Voltage-gated sodium channels (Nav) on sensory nerve membranesSmall molecule
Ocular Anesthesia
Ocular Surface Anesthesia
Modafinil(Provigil)
Approved
Sympathomimetic-like AgentSmall molecule
Narcolepsy
Approved
Glutathione precursor (cysteine donor)Small molecule
Toxicology / Acetaminophen Overdose
Acetaminophen Overdose
Approved
H. pylori eradication (PPI + amoxicillin + rifabutin)Small molecule
Helicobacter pylori Infection

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026PresentationCapsaicin (Qutenza)Phase III RISE results at IASP 2026: one of the primary endpoints met (average pain intensity, weeks 2-12)
20 August 2026Topline resultchloroprocaineIHEEZO contralateral-eye study vs proparacaine in intravitreal injections
9 December 2024ApprovalN-acetylcysteineFDA approves Acetadote sNDA for simplified dosing regimen
US, FDA · Source ↗

Financial reports

No financial reports recorded.